AEON Biopharma Statistics
Share Statistics
AEON Biopharma has 11.31M
shares outstanding. The number of shares has increased by 861.53%
in one year.
| Shares Outstanding | 11.31M |
| Shares Change (YoY) | 861.53% |
| Shares Change (QoQ) | 841.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 176.61K, so 1.56% of the outstanding
shares have been sold short.
| Short Interest | 176.61K |
| Short % of Shares Out | 1.56% |
| Short % of Float | 1.57% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 0.01 and the forward
PE ratio is null.
AEON Biopharma's PEG ratio is
0.
| PE Ratio | 0.01 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -0.01 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for AEON Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11,
with a Debt / Equity ratio of -0.45.
| Current Ratio | 0.11 |
| Quick Ratio | 0.11 |
| Debt / Equity | -0.45 |
| Debt / EBITDA | -0.47 |
| Debt / FCF | -0.64 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $8,401,000 |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.38, so AEON Biopharma's
price volatility has been higher than the market average.
| Beta | 0.38 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 31.34 |
| Relative Strength Index (RSI) | 46.73 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | 72.98M |
| Net Income | 42.01M |
| EBITDA | -27.73M |
| EBIT | -27.82M |
| Earnings Per Share (EPS) | 5597.28 |
Full Income StatementBalance Sheet
The company has 13K in cash and 12.96M in
debt, giving a net cash position of -12.94M.
| Cash & Cash Equivalents | 13K |
| Total Debt | 12.96M |
| Net Cash | -12.94M |
| Retained Earnings | -431.6M |
| Total Assets | 3.14M |
| Working Capital | -12.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -20.29M
and capital expenditures 0, giving a free cash flow of -20.29M.
| Operating Cash Flow | -20.29M |
| Capital Expenditures | n/a |
| Free Cash Flow | -20.29M |
| FCF Per Share | -2703.8 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
